Morgan Stanley analyst Terence Flynn maintained a Buy rating on Gilead Sciences yesterday and set a price target of $143.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Terence Flynn has given his Buy rating due to a combination of factors that highlight Gilead Sciences’ potential for growth and profitability. The ongoing launch of Yeztugo, particularly in the HIV PrEP market, is a significant driver for the company’s future revenue, with Flynn increasing the third-quarter estimates based on recent script data. This launch is expected to provide an upside to the company’s financial estimates, positioning Gilead favorably against its peers.
Additionally, Flynn’s analysis considers the potential impacts of recent policy changes, such as the Trump administration’s MFN policy and the possibility of Biktarvy being included in future Medicare price negotiations. Despite these challenges, the company’s revenue and EPS growth projections remain strong, with a CAGR that is competitive within the industry. The stock’s current trading multiple also suggests room for further expansion, supporting Flynn’s optimistic outlook on Gilead’s strategic advancements and policy developments.
According to TipRanks, Flynn is a 4-star analyst with an average return of 3.5% and a 54.84% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Bristol-Myers Squibb, and BioNTech SE.
In another report released on September 30, Bernstein also maintained a Buy rating on the stock with a $135.00 price target.